9th IAS Conference on HIV Science (IAS 2017), Paris, France, 23-26 July 2017

第九届 IAS HIV 科学会议 (IAS 2017)，法国巴黎，2017 年 7 月 23-26 日

• 批准号: 9339774
• 负责人: Linda-Gail Gail Bekker
• 金额: $ 70万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-12 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9339774
• 关键词: AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adherence; Adolescent; Adverse effects; Africa; Aging; Antiviral Agents; Area; Asia; Basic Science; Cardiovascular system; Caring; Central Asia; Cessation of life; Cities; Clinical Research; Clinical Sciences; Cognitive; Communities; Comorbidity; Continuity of Patient Care; Country; Data; Development; Discrimination; Disease remission; Eastern Europe; Ensure; Epidemic; Epidemiology; Europe; Financial Support; France; General Population; Goals; HIV; HIV Infections; HIV/TB; Hepatitis B; Hepatitis C; Human Rights; Human immunodeficiency virus test; Immune; Individual; Infection; Inflammation; Injecting drug user; International; Kidney; Knowledge; Leadership; Life; Life Expectancy; Link; Malaria; Malignant Neoplasms; Metabolic; Methods; Middle East; Nomads; Northern Africa; Oral; Paris, France; Pathogenesis; Pathway interactions; Patients; Pharmaceutical Preparations; Policies; Policy Maker; Politics; Population; Population Heterogeneity; Prevention; Preventive vaccine; Public Health; Refugees; Regimen; Research; Research Personnel; Research Priority; Science; Scientific Advances and Accomplishments; Scientist; Services; System; Technology; Testing; Time; Topical application; Translating; Translations; Treatment outcome; Tuberculosis; Vaccination; Vaccines; Viral; Viral hepatitis; Vision; anticancer research; base; bone; co-infection; cost effective; cost effectiveness; drug development; frontier; implementation research; implementation science; improved; innovation; insight; meetings; men who have sex with men; multidisciplinary; novel; novel marker; novel therapeutics; optimism; passive antibodies; pre-exposure prophylaxis; precision medicine; prevent; programs; research and development; response; scale up; sex; social stigma; symposium; synergism; therapeutic vaccine; tool; transgender; treatment strategy; trend; uptake

Project Summary - Significant scientific advances were made in the last few years that contribute to better HIV prevention and treatment outcomes and increased cost-effectiveness but major challenges remain that could undermine the attainment of the global goal to end AIDS as a public health threat: Better treatment and vaccines remain an urgent challenge to address the HIV/TB epidemic. Much more is needed to effect scale up and optimize treatment strategies in high-burden regions. Globally challenges remain in reaching ambitious targets across the continuum of care. Concrete innovations are urgently needed to improve HIV testing and its uptake and to retain individuals successfully in life-long care. This is particularly evident in adolescent populations. IAS 2017 will contribute to addressing some of the continuing challenges in HIV prevention, treatment and care in a scientific program that will integrate innovative approaches, such as the active application of avant-garde technologies in basic science and implementation research, and precision medicine as a bridging theme. France’s key role in HIV science and the strong political will enabling a rapid translation of science into policy, along with the country’s strong links with countries in Africa and Asia, will be defining factors for a scientific conference program that will present latest science from across the globe and discuss its translation into a variety of specific epidemiological and policy contexts. IAS 2017, taking place in Paris on 23-26 July 2017, has an expected attendance of 6,000 to 7,000 delegates from more than 120 countries. The specific aims of IAS 2017 are to: 1. Accelerate basic science and innovation for the development of new prevention, treatment and care options; 2. Strengthen research towards remission off treatment and a vaccine; 3. Enhance knowledge transfer and sharing between HIV and co-infections, including tuberculosis, viral hepatitis, malaria, and co-morbidities; 4. Strengthen the implementation science research agenda to address key barriers and challenges across the HIV prevention and treatment cascades in a variety of epidemic scenarios; 5. Explore the links between HIV and human rights. The scientific program will consist of four tracks: Basic Science; Clinical Science; Prevention Science; Implementation Science. A symposium on HIV cure and cancer research with a further focus on therapeutic vaccines will be organized in conjunction with the conference. Cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives; bridging sessions cut across at least two of the tracks to provide opportunities for multi-disciplinary dialogues. The participation of young researchers, basic scientists and researchers in related fields such as non-communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support.

项目摘要-过去几年取得的重大科学进步有助于改善艾滋病毒